These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 16702386)

  • 1. Common genetic variation at PTEN and risk of sporadic breast and prostate cancer.
    Haiman CA; Stram DO; Cheng I; Giorgi EE; Pooler L; Penney K; Le Marchand L; Henderson BE; Freedman ML
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):1021-5. PubMed ID: 16702386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.
    Freedman ML; Penney KL; Stram DO; Riley S; McKean-Cowdin R; Le Marchand L; Altshuler D; Haiman CA
    Cancer Res; 2005 Aug; 65(16):7516-22. PubMed ID: 16103107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.
    Haiman CA; Stram DO; Pike MC; Kolonel LN; Burtt NP; Altshuler D; Hirschhorn J; Henderson BE
    Hum Mol Genet; 2003 Oct; 12(20):2679-92. PubMed ID: 12944421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic assessment of common genetic variation in CYP11A and risk of breast cancer.
    Setiawan VW; Cheng I; Stram DO; Giorgi E; Pike MC; Van Den Berg D; Pooler L; Burtt NP; Le Marchand L; Altshuler D; Hirschhorn J; Henderson BE; Haiman CA
    Cancer Res; 2006 Dec; 66(24):12019-25. PubMed ID: 17178901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort.
    Freedman ML; Penney KL; Stram DO; Le Marchand L; Hirschhorn JN; Kolonel LN; Altshuler D; Henderson BE; Haiman CA
    Hum Mol Genet; 2004 Oct; 13(20):2431-41. PubMed ID: 15317758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
    Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
    Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
    Sun J; Wiklund F; Zheng SL; Chang B; Bälter K; Li L; Johansson JE; Li G; Adami HO; Liu W; Tolin A; Turner AR; Meyers DA; Isaacs WB; Xu J; Grönberg H
    J Natl Cancer Inst; 2005 Apr; 97(7):525-32. PubMed ID: 15812078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
    Cox DG; Blanché H; Pearce CL; Calle EE; Colditz GA; Pike MC; Albanes D; Allen NE; Amiano P; Berglund G; Boeing H; Buring J; Burtt N; Canzian F; Chanock S; Clavel-Chapelon F; Feigelson HS; Freedman M; Haiman CA; Hankinson SE; Henderson BE; Hoover R; Hunter DJ; Kaaks R; Kolonel L; Kraft P; LeMarchand L; Lund E; Palli D; Peeters PH; Riboli E; Stram DO; Thun M; Tjonneland A; Trichopoulos D; Yeager M;
    Breast Cancer Res; 2006; 8(5):R54. PubMed ID: 16987421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis.
    Pearce CL; Hirschhorn JN; Wu AH; Burtt NP; Stram DO; Young S; Kolonel LN; Henderson BE; Altshuler D; Pike MC
    J Natl Cancer Inst; 2005 Jan; 97(1):51-9. PubMed ID: 15632380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer.
    Chen YC; Giovannucci E; Lazarus R; Kraft P; Ketkar S; Hunter DJ
    Cancer Res; 2005 Dec; 65(24):11771-8. PubMed ID: 16357190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor beta polymorphism is associated with prostate cancer risk.
    Thellenberg-Karlsson C; Lindström S; Malmer B; Wiklund F; Augustsson-Bälter K; Adami HO; Stattin P; Nilsson M; Dahlman-Wright K; Gustafsson JA; Grönberg H
    Clin Cancer Res; 2006 Mar; 12(6):1936-41. PubMed ID: 16551880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study.
    Le Marchand L; Haiman CA; van den Berg D; Wilkens LR; Kolonel LN; Henderson BE
    Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):412-5. PubMed ID: 15006917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer.
    Chen YC; Giovannucci E; Kraft P; Lazarus R; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):1982-9. PubMed ID: 17932345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
    McKay JD; McCullough ML; Ziegler RG; Kraft P; Saltzman BS; Riboli E; Barricarte A; Berg CD; Bergland G; Bingham S; Brustad M; Bueno-de-Mesquita HB; Burdette L; Buring J; Calle EE; Chanock SJ; Clavel-Chapelon F; Cox DG; Dossus L; Feigelson HS; Haiman CA; Hankinson SE; Hoover RN; Hunter DJ; Husing A; Kaaks R; Kolonel LN; Le Marchand L; Linseisen J; McCarty CA; Overvad K; Panico S; Purdue MP; Stram DO; Stevens VL; Trichopoulos D; Willett WC; Yuenger J; Thun MJ
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):297-305. PubMed ID: 19124512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor genotypes and haplotypes associated with breast cancer risk.
    Gold B; Kalush F; Bergeron J; Scott K; Mitra N; Wilson K; Ellis N; Huang H; Chen M; Lippert R; Halldorsson BV; Woodworth B; White T; Clark AG; Parl FF; Broder S; Dean M; Offit K
    Cancer Res; 2004 Dec; 64(24):8891-900. PubMed ID: 15604249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort.
    Cheng I; Penney KL; Stram DO; Le Marchand L; Giorgi E; Haiman CA; Kolonel LN; Pike M; Hirschhorn J; Henderson BE; Freedman ML
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1993-7. PubMed ID: 17035411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer.
    Nam RK; Zhang WW; Loblaw DA; Klotz LH; Trachtenberg J; Jewett MA; Stanimirovic A; Davies TO; Toi A; Venkateswaran V; Sugar L; Siminovitch KA; Narod SA
    Prostate Cancer Prostatic Dis; 2008; 11(3):241-6. PubMed ID: 17876339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels.
    Kathiresan S; Gabriel SB; Yang Q; Lochner AL; Larson MG; Levy D; Tofler GH; Hirschhorn JN; O'Donnell CJ
    Circulation; 2005 Sep; 112(12):1728-35. PubMed ID: 16172282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 gene promoter haplotypes and prostate cancer risk.
    Panguluri RC; Long LO; Chen W; Wang S; Coulibaly A; Ukoli F; Jackson A; Weinrich S; Ahaghotu C; Isaacs W; Kittles RA
    Carcinogenesis; 2004 Jun; 25(6):961-6. PubMed ID: 14754878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.